Clarke A M, Zemcov S J
J Antimicrob Chemother. 1984 Feb;13(2):121-8. doi: 10.1093/jac/13.2.121.
The in-vitro activity of ticarcillin in combination with clavulanic acid was compared with that of ticarcillin alone, piperacillin, cefotaxime and, where appropriate, other beta-lactams against a total of 301 recent clinical isolates and characterized beta-lactamase producers. An agar dilution procedure was used to determine MICs and two inocula (10(4) and 10(6) cfu) were used throughout. MICs of the combination of ticarcillin and clavulanic acid were expressed as MICs of ticarcillin in the presence of 5 or 10 mg/l of clavulanic acid. Against most members of the Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii and Serratia marcescens), ticarcillin plus clavulanic acid was as active as or more active than piperacillin. Against Staphylococcus aureus. Haemophilus influenzae and the Bacteroides fragilis group the combination was considerably more active than piperacillin. Piperacillin was more active than the ticarcillin/clavulanic acid combination against Pseudomonas aeruginosa.
将替卡西林与克拉维酸联合使用的体外活性,与单独使用替卡西林、哌拉西林、头孢噻肟以及在适当情况下与其他β-内酰胺类药物,针对总共301株近期临床分离株和已鉴定的β-内酰胺酶产生菌进行了比较。采用琼脂稀释法测定最低抑菌浓度(MIC),并始终使用两种接种量(10⁴和10⁶cfu)。替卡西林与克拉维酸联合使用时的MIC,以在5或10mg/L克拉维酸存在下替卡西林的MIC表示。对于大多数肠杆菌科细菌(大肠杆菌、肺炎克雷伯菌、奇异变形杆菌、斯氏普罗威登斯菌和粘质沙雷菌),替卡西林加克拉维酸与哌拉西林的活性相当或更高。对于金黄色葡萄球菌、流感嗜血杆菌和脆弱拟杆菌属,联合用药比哌拉西林的活性显著更高。哌拉西林对铜绿假单胞菌的活性比替卡西林/克拉维酸联合用药更高。